

1 **Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs**  
2 **in the San Diego-Tijuana border region**

3 Steffanie A. Strathdee<sup>1\*</sup>, Daniela Abramovitz<sup>1</sup>, Alicia Harvey-Vera<sup>1,2,4</sup>, Carlos Vera<sup>1</sup>, Gudelia Rangel<sup>3,4</sup>,  
4 Irina Artamonova<sup>1</sup>, Antoine Chaillon<sup>1</sup>, Caroline Ignacio<sup>5</sup>, Alheli Calderon<sup>1,6</sup>, Natasha K. Martin<sup>1</sup>, Thomas L.  
5 Patterson<sup>7</sup>

6 **Affiliations:** <sup>1</sup>Division of Infectious Diseases and Global Public Health, Department of Medicine,  
7 University of California San Diego, La Jolla, CA, United States of America; <sup>2</sup>Universidad Xochicalco,  
8 Facultad de Medicina, Campus Tijuana, Mexico; <sup>3</sup>Departamento de Estudios de Población, El Colegio de  
9 la Frontera Norte, Tijuana, Mexico; <sup>4</sup>United States-Mexico Border Health Commission, Tijuana, Mexico;  
10 <sup>5</sup>CFAR Translational Virology Core, Department of Medicine, University of California San Diego, La Jolla,  
11 CA, United States of America; <sup>6</sup>School of Public Health, San Diego State University, San Diego,  
12 California, United States of America; <sup>7</sup>Department of Psychiatry, University of California, San Diego, La  
13 Jolla, CA, United States of America

14 \*Corresponding Author:

15 E-mail: [sstrathdee@health.ucsd.edu](mailto:sstrathdee@health.ucsd.edu)

16

## 17 **Abstract**

18 Background: People who inject drugs may be at elevated SARS-CoV-2 risk due to their living conditions  
19 and/or exposures when seeking or using drugs. No study to date has reported upon risk factors for  
20 SARS-CoV-2 infection among people who inject drugs or sex workers.

21 Methods and Findings: Between October, 2020 and June, 2021, participants aged  $\geq 18$  years from San  
22 Diego, California, USA and Tijuana, Baja California, Mexico who injected drugs within the last month  
23 underwent interviews and testing for SARS-CoV-2 RNA and antibodies. Binomial regressions identified  
24 correlates of SARS-CoV-2 seropositivity. Of 386 participants, SARS-CoV-2 seroprevalence was 36.3%  
25 (95% CI: 31.5%-41.1%); 92.1% had detectable IgM antibodies. Only 37.5% had previously been tested.  
26 Seroprevalence did not differ by country of residence. None tested RNA-positive. Most (89.5%) reported  
27 engaging in  $\geq 1$  protective behavior [e.g., facemasks (73.5%), social distancing (46.5%), or increasing  
28 handwashing/sanitizers (22.8%)]. In a multivariate model controlling for sex, older age, and  
29 Hispanic/Latinx/Mexican ethnicity were independently associated with SARS-CoV-2 seropositivity, as was  
30 engaging in sex work (AdjRR: 1.63; 95% CI: 1.18-2.27) and having been incarcerated in the past six  
31 months (AdjRR: 1.49; 95% CI: 0.97-2.27). Presence of comorbidities and substance using behaviors  
32 were not associated with SARS-CoV-2 seropositivity.

33 Conclusions: This is the first study to show that sex work and incarceration were independently  
34 associated with SARS-CoV-2 infection. Despite engaging in protective measures, over one-third had  
35 evidence of infection, reinforcing the need for a coordinated binational response. Risk mitigation and  
36 vaccination is especially needed among older and Hispanic people who inject drugs and those with less  
37 agency to protect themselves, such as those who are sex workers or incarcerated.

38

## 39 Introduction

40 The disproportionate burden of COVID-19 on under-represented minorities is well documented [1–3].  
41 However, data are lacking on people with substance use disorders who may be vulnerable to acquiring  
42 and transmitting SARS-CoV-2 due to their living conditions (e.g., homelessness, incarceration) and drug-  
43 related behaviors (e.g. smoking, vaping, sharing drug paraphernalia, sex work) [4,5]. In a nation-wide  
44 study, those with substance use disorders, especially African Americans and opioid users, were at  
45 increased risk of COVID-19 [6]. However, this study could not determine whether these factors were  
46 independently associated with COVID-19 diagnosis since risk factor data were not available, and the  
47 sample was restricted to patients accessing health care. In a telephone survey of active and former drug  
48 injectors in Baltimore, Maryland, compared to former substance users, those who were actively using  
49 substances were less likely to report social distancing [5]. There is also evidence that the COVID-19  
50 pandemic has interrupted drug supplies as well as harm reduction and addiction treatment services [7].  
51 Most epidemiologic research on COVID-19 has been conducted on inpatient samples and has focused on  
52 upper-income countries. We studied prevalence and correlates of SARS-CoV-2 infection in a binational  
53 community-based study of people who inject drugs residing in San Diego, California and Tijuana, Baja  
54 California, Mexico. We hypothesized *a priori* that residents of San Diego who had recently crossed the  
55 border to inject drugs in Tijuana and those who were homeless, traded sex or injected drugs more often  
56 would be more likely to test SARS-CoV-2 seropositive.

## 57 Materials and methods

58 Study Setting: As the eighth largest city in the U.S. and the largest situated on the Mexico-US border,  
59 San Diego County, California is home to approximately 1.42 million people. Its counterpart in Baja  
60 California, Mexico is Tijuana, a city of ~1.5 million people, located twenty minutes from San Diego and  
61 located on a major drug trafficking route. In an attempt to limit SARS-CoV-2 transmission, the U.S.-  
62 Mexico border was closed to essential travel on March 21, 2020 for the eight months duration of the  
63 study.

64 Participants and Eligibility. Between October 28, 2020 and June 16, 2021, street outreach was used to  
65 recruit participants aged  $\geq 18$  or older who injected drugs within the last month and reported living in San  
66 Diego County or Tijuana. We sought to enroll participants residing in San Diego who reported having  
67 crossed the border to inject drugs in Tijuana within the last two years as well as those from either city who  
68 reported not having used illicit drugs on the other side of the border.

69 Survey Measures: After providing informed consent, participants underwent interviewer-administered  
70 surveys at baseline and approximately one week later to minimize participant burden. Computer assisted  
71 personal interviewing was used to minimize socially desirable responding. Survey items included  
72 sociodemographics, potential COVID-19 exposures (e.g., injection and non-injection drug use, sharing  
73 injection equipment, incarceration, sex work), vulnerabilities (e.g., homelessness, cross-border, mobility,  
74 food insecurity [8], impact of COVID-19 on income and housing), and protective behaviors (e.g., social  
75 distancing, use of face masks and handwashing/sanitizers). Participants were compensated \$20 USD.  
76 Protocols were approved by institutional review boards at the University of California San Diego and  
77 Xochicalco University.

78 SARS-CoV-2 Antibody Detection. Serology was conducted by Genalyte® (San Diego, CA), using their  
79 Maverick™ Multi-Antigen Serology Panel [9] that detects IgG and IgM antibodies to five SARS-CoV-2  
80 antigens (Nucleocapsid, Spike S1-S2, Spike S1, Spike S1-RBD, Spike S2) within a multiplex format  
81 based on photonic ring resonance. A machine learning algorithm was used to call results using the  
82 Random Forest Ensemble method with 3000 decision trees [10].

83 SARS-CoV-2 RNA Detection: Participants self-collected anterior nasal swabs which were placed in 3mL  
84 of viral transport media and stored for up to one week at 80 degrees Celsius before being shipped on ice  
85 for testing at the University of California San Diego (UCSD)'s Center for AIDS Research. RT-PCR was  
86 conducted using a pooling approach based on the Fluxergy system® (Irvine, CA) to detect SARS-CoV-2  
87 RNA.

88 HIV and HCV Serology. Rapid HIV and HCV tests were conducted using the Miriad® HIV/HCV Antibody  
89 InTec Rapid Anti-HCV Test (Avantor, Radnor, PA). Reactive and indeterminate tests underwent a second  
90 rapid test with Oraquick® HIV or Oraquick® HCV, respectively (Orasure, Bethlehem, PA).

91 Statistical Analysis: SARS-CoV-2 prevalence was calculated with 95% confidence intervals (CIs) based  
92 on the Binomial distribution. Those testing indeterminate were excluded. The Cochran-Armitage test was  
93 used to assess trends in SARS-CoV-2 seroprevalence.

94 Characteristics of participants testing SARS-CoV-2 seropositive versus seronegative were compared  
95 using Wilcoxon Rank Sum for continuous variables and Chi-square or Fisher's Exact tests for categorical  
96 variables. Univariate and multivariable binomial regressions with robust standard error estimation via  
97 generalized estimating equations were performed to identify factors associated with SARS-CoV-2  
98 seropositivity. Variables attaining <10% significance were considered for inclusion in multivariable  
99 models. All potential interactions between variables in the final model were assessed. Multi-collinearity  
100 was assessed using diagnostics such as largest condition index and variance inflation factors. Although  
101 site-specific models were examined, results were presented for the overall sample since associations  
102 were generally similar.

103 Role of funding source: The funders had no involvement in the study design, collection, analysis,  
104 interpretation or writing of this rpreport, nor the decision to submit the paper for publication.

## 105 **Results**

106 Of 405 participants tested, none had detectable SARS-CoV-2 RNA. Considering serologic evidence of  
107 SARS-CoV-2 infection, 19 (4.7%) tested indeterminate and were excluded. Detectable SARS-CoV-2 IgG  
108 and/or IgM antibodies were observed in 36.3% [95% confidence interval (95% CI): 31.5%-41.1%], of  
109 whom the majority had IgM (92.1%). Of the 140 testing SARS-CoV-2 seropositive, only 37.5% had  
110 previously been tested, and 26.8% reported  $\geq 1$  current symptom consistent with COVID-19. There was no  
111 significant trend in seroprevalence over time ( $p=0.80$ ).

112 Of the 386 subjects included in the analysis, 63.5% lived in San Diego County. Most were male (74.1%)  
113 and Hispanic/Latinx/Mexican (71.5%). Median age was 43 (inter-quartile range [IQR: 35-51]). Over half  
114 reported that COVID-19 had adversely affected their housing or income. During the last six months,  
115 39.1% were homeless, 8.3% were incarcerated and 12.4% traded sex (Table 1). Of the San Diego  
116 residents, 50.8% reported having crossed the border to inject drugs in Tijuana within the last six months.

117 Older age and identifying as Hispanic, Latinx, or Mexican were significantly associated with SARS-CoV-2  
 118 seropositivity (Table 1). Considering potential community exposures in the past six months (Table 2),  
 119 those engaging in sex work were significantly more likely to test seropositive compared to those who did  
 120 not (17.9% vs. 9.3%,  $p=0.01$ , [Relative Risk (RR): 1.53; 95% CI: 1.12-2.09]. Being incarcerated was  
 121 associated with marginally higher SARS-CoV-2 seropositivity (RR: 1.43; 95% CI: 0.99-2.09). We did not  
 122 observe injection drug use, smoking, vaping specific drugs or any other substance use behaviors to be  
 123 associated with seroprevalence, nor were any co-morbidities (i.e., HIV, HCV, Type 2 diabetes,  
 124 hypertension).

**Table 1. Characteristics Associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico (N=386)**

<b>Baseline Characteristics</b>	<b>SARS-CoV-2 Seropositive N=140</b>	<b>SARS-CoV-2 Seronegative N=246</b>	<b>Total N=386</b>	<b>P-value</b>
<b><i>Sociodemographics</i></b>				
Male	104(74.3%)	182(74.0%)	286(74.1%)	.95
Median Age (IQR)	45.0(37.0,53.0)	42.0(34.0,50.0)	43.0(35.0,51.0)	.042
Hispanic/Latinx/Mexican	111(79.3%)	165(67.1%)	276(71.5%)	.01
Speaks English	98(70.0%)	185(75.2%)	283(73.3%)	.27
Born in the US	61(43.6%)	129(52.4%)	190(49.2%)	.09
Primary residence in San Diego	88(62.9%)	157(63.8%)	245(63.5%)	.85
Highest year of school completed (IQR)	11.0(8.0,12.0)	11.0(7.0,12.0)	11.0(7.0,12.0)	.99
Married or common law	25(17.9%)	49(19.9%)	74(19.2%)	.62
Average monthly income <500 USD	75(53.6%)	130(52.8%)	205(53.1%)	.89
Median years lived in Study Location (IQR)	30.0(10.0,45.0)	26.5(10.0,40.0)	28.0(10.0,41.0)	.20
<b><i>Potential Exposures</i></b>				
Homeless*	50(35.7%)	101(41.1%)	151(39.1%)	.30
Incarcerated*	16(11.5%)	16(6.5%)	32(8.3%)	.12
Median # of people in household (IQR)*	2.0(1.0, 4.0)	2.0(1.0, 5.0)	2.0(1.0, 4.0)	.71
Low/very low food security	88(78.6%)	171(80.3%)	259(79.7%)	.72
Engaged in sex work*	25(17.9%)	23(9.3%)	48(12.4%)	.01
Client of sex worker*	8(5.7%)	10(4.1%)	18(4.7%)	.46
Exposed to someone with COVID-19	6(5.4%)	12(5.6%)	18(5.5%)	1.0
<b><i>Impact of Pandemic</i></b>				
Housing situation worse	91(65.0%)	140(56.9%)	231(59.8%)	.12
Income worse	98(70.5%)	149(62.3%)	247(65.3%)	.11
<b><i>Substance Use</i></b>				
Smokes cigarettes	118(84.3%)	222(90.2%)	340(88.1%)	.08

**Table 1 (continued). Characteristics Associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico (N=386)**

<b>Baseline Characteristics</b>	<b>SARS-CoV-2 Seropositive N=140</b>	<b>SARS-CoV-2 Seronegative N=246</b>	<b>Total N=386</b>	<b>P-value</b>
Smoked or vaped marijuana*	67(47.9%)	139(56.5%)	206(53.4%)	.10
Smoked/snorted/inhaled heroin*	32(22.9%)	73(29.7%)	105(27.2%)	.15
Smoked/snorted/inhaled/vaped meth*	86(61.4%)	150(61.0%)	236(61.1%)	.93
Smoked/snorted/inhaled crack/cocaine*	15(10.7%)	22(8.9%)	37(9.6%)	.57
Injected heroin*	123(87.9%)	222(90.2%)	345(89.4%)	.46
Injected fentanyl*	27(19.3%)	50(20.3%)	77(19.9%)	.81
Median age at first injection	20.0(17.0,27.0)	19.0(17.0,25.0)	20.0(17.0,26.0)	.36
#Times injected drugs per day	2.5(0.3, 4.0)	2.5(0.7, 4.0)	2.5(0.3, 4.0)	.14
Visited shooting galleries*	12(8.6%)	19(7.7%)	31(8.0%)	.77
Used hit doctor*	25(17.9%)	46(18.8%)	71(18.4%)	.82
Crossed border to inject drugs*	60(42.9%)	97(39.4%)	157(40.7%)	.51
<b>Co-Morbidities</b>				
HIV-antibody positive	15(10.7%)	17(6.9%)	32(8.3%)	.25
HCV-antibody positive	47(33.6%)	86(35.1%)	133(34.5%)	.82
Diabetes <sup>Y</sup>	5(4.5%)	10(4.7%)	15(4.6%)	.92
Asthma <sup>Y</sup>	8(7.1%)	22(10.3%)	30(9.2%)	.35
Hypertension <sup>Y</sup>	13(11.6%)	25(11.7%)	38(11.7%)	.97
<b>Preventive Measures</b>				
Practiced social distancing <sup>Y</sup>	52(46.4%)	99(46.5%)	151(46.5%)	1.0
Wore face mask <sup>Y</sup>	85(75.9%)	154(72.3%)	239(73.5%)	.51
Increased handwashing/sanitizer <sup>Y</sup>	24(21.4%)	50(23.5%)	74(22.8%)	.78
Stocked up on drugs <sup>Y</sup>	18(16.1%)	35(16.5%)	53(16.4%)	1.0
Stocked up on harm reduction supplies <sup>Y</sup>	24(21.4%)	38(17.9%)	62(19.1%)	.45
Stopped smoking (current smokers) <sup>Y</sup>	6(6.3%)	4(2.1%)	10(3.5%)	.09
Avoided sharing drug paraphernalia <sup>Y</sup>	11(9.8%)	18(8.5%)	29(9.0%)	.69
Engaged in ≥1 protective behavior <sup>Y</sup>	101(90.2%)	190(89.2%)	291(89.5%)	.78
Had a prior COVID-19 test <sup>Y</sup>	42(37.5%)	63(29.6%)	105(32.3%)	.17

125

**Table 2: Factors associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico**

<b>Baseline Characteristics</b>	<b>Univariate RR (95% CI)</b>
<b>Sociodemographics</b>	
Male	1.01 ( 0.75,1.37 )
Age <sup>¶P</sup>	1.02 ( 1.00,1.03 )
Hispanic/Latinx/Mexican <sup>P</sup>	1.53 ( 1.08,2.15 )
Speaks English	0.85 ( 0.64,1.13 )
Born in the US	0.80 ( 0.61,1.04 )

**Table 2 (continued): Factors associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico**

<b>Baseline Characteristics</b>	<b>Univariate RR (95% CI)</b>
<b><i>Sociodemographics (con't)</i></b>	
Highest year of school completed‡	1.00 ( 0.96,1.04 )
Married or common law	0.92 ( 0.65,1.30 )
Average monthly income <500 USD	1.02 ( 0.78,1.33 )
Primary residence in San Diego	0.97 ( 0.74,1.28 )
Years lived in Study Location‡	1.01 ( 1.00,1.01 )
<b><i>Potential Exposures</i></b>	
Homeless*	0.86 ( 0.65,1.14 )
Incarcerated* <sup>P</sup>	1.43 ( 0.99,2.09 )
Median # of people in household*‡	1.00 ( 1.00,1.00 )
Low/very low food security	0.93 ( 0.65,1.34 )
Engaged in sex work* <sup>P</sup>	1.53 ( 1.12,2.09 )
Client of sex worker*	1.24 ( 0.73,2.11 )
Exposed to someone with COVID-19	0.97 ( 0.49,1.89 )
<b><i>Impact of Pandemic</i></b>	
Housing situation worse	1.25 ( 0.94,1.65 )
Income worse	1.27 ( 0.94,1.71 )
<b><i>Substance Use</i></b>	
Smokes cigarettes	0.73 ( 0.52,1.01 )
Smoked or vaped marijuana*	0.80 ( 0.62,1.04 )
Smoked/snorted/inhaled heroin* <sup>P</sup>	0.79 ( 0.57,1.10 )
Smoked/snorted/inhaled/vaped meth*	1.01 ( 0.77,1.33 )
Smoked/snorted/inhaled crack/cocaine*	1.13 ( 0.75,1.71 )
Injected heroin*	0.86 ( 0.58,1.27 )
Injected fentanyl*	0.96 ( 0.68,1.34 )
Median age at first injection‡	1.01 ( 0.99,1.02 )
#Times injected drugs per day‡	0.94 ( 0.87,1.02 )
Visited shooting galleries*	1.07 ( 0.67,1.71 )
Used hit doctor*	0.96 ( 0.68,1.36 )
Crossed border to inject drugs*	1.09 ( 0.84,1.43 )
<b><i>Co-Morbidities</i></b>	
HIV-antibody positive	1.33 ( 0.89,1.97 )
HCV-antibody positive	0.96 ( 0.72,1.27 )
Diabetes <sup>Y</sup>	0.97 ( 0.46,2.01 )
Asthma <sup>Y</sup>	0.76 ( 0.41,1.40 )
Hypertension <sup>Y</sup>	0.99 ( 0.62,1.58 )
<b><i>Preventive Measures</i></b>	
Practiced social distancing <sup>Y</sup>	1.00 ( 0.74,1.35 )
Wore face mask <sup>Y</sup>	1.13 ( 0.79,1.62 )



**Table 2 (continued): Factors associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico**

Baseline Characteristics	Univariate RR (95% CI)
<b>Preventive Measures (con't)</b>	
Increased handwashing/sanitizer <sup>Y</sup>	0.93 ( 0.64,1.34 )
Stocked up on drugs <sup>Y</sup>	0.98 ( 0.65,1.47 )
Stocked up on harm reduction supplies <sup>Y</sup>	1.15 ( 0.81,1.65 )
Stopped smoking (among current smokers) <sup>Y<sup>P</sup></sup>	1.86 ( 1.09,3.17 )
Avoided sharing drug paraphernalia <sup>Y</sup>	1.11 ( 0.68,1.81 )
Engaged in ≥1 protective behavior <sup>Y</sup>	1.07 ( 0.64,1.79 )
Had a prior COVID-19 test <sup>Y<sup>P</sup></sup>	1.26 ( 0.93,1.70 )

126 \*past 6 months; <sup>Y</sup> Missing values: n=66 ‡ Per year increase; <sup>P</sup>P-value<0.10

127

128 In a multivariate model that controlled for sex (Table 3), each year in age was associated with a 2%

129 increase in SARS-CoV-2 seropositivity (Adjusted relative risk (AdjRR): 1.02; 95% CI: 1.01-1.03).

130 Identifying as Hispanic/Latinx/Mexican was also independently associated with SARS-CoV-2

131 seropositivity (AdjRR: 1.53; 95% CI: 1.09-2.15), as was engaging in sex work in the past six months

132 (adjRR: 1.63; 95% CI: 1.18-2.27). Being incarcerated in the last six months remained marginally

133 significant (AdjRR: 1.49; 95% CI: 0.97-2.27). When country of residence was forced into the model, all

134 significant associations held except ethnicity. Excluding nine participants who reported having received at

135 least one COVID-19 vaccine did not appreciably change parameter estimates.

**Table 3: Factors Independently associated with SARS-CoV-2 Seropositivity among People who Inject Drugs in San Diego, CA and Tijuana, Mexico**

Baseline Characteristics	Adjusted RR** (95% CI)
Male	1.02 (0.76, 1.37)
Age <sup>‡</sup>	1.02 (1.01, 1.03)
Hispanic/Latinx/Mexican	1.53 (1.09, 2.15)
Engaged in sex work*	1.63 (1.18, 2.27)
Incarcerated*	1.49 (0.97, 2.27)

136 \*past 6 months; \*\*variables in the multivariable model were adjusted for all the variables in the model;

137 ‡ Per year increase

138

139 Although 89.5% reported engaging in ≥1 protective behavior [e.g., face masks (73.5%)], only 46.5%

140 reported social distancing, 22.8% increased handwashing/hand sanitizers, and 9.0% reported avoiding

141 sharing drug paraphernalia in the prior six months (Table 1). None of these behaviors were significantly

142 associated with SARS-CoV-2 serostatus. Those testing SARS-CoV-2 seropositive were more likely to  
143 report having stopped smoking in the last six months and to have had a COVID-19 test.

144 Compared to non-sex workers, sex workers were just as less likely report protective behaviors but were  
145 significantly more likely to report being exposed to someone with COVID-19 (20% vs. 3.8%,  $p=0.001$ ) or  
146 to have low/very low food security (94.3% vs. 77.9%  $p=0.02$ ).

## 147 **Discussion**

148 In this community-based study of people who inject drugs in the San Diego-Tijuana border region, over  
149 one third had detectable SARS-CoV-2 antibodies, which exceeds estimates from the general population  
150 in either city. Modeling of the SARS-CoV-2 epidemic in San Diego County suggests that prevalence was  
151 below 5% through July, 2020 then increased to approximately 20% by January, 2021 (California  
152 Department of Public Health, unpublished data). In a household study conducted in Tijuana in February  
153 2021, SARS-CoV-2 seroprevalence was 21% [11]. Reports in the literature of SARS-CoV-2 prevalence  
154 among people who inject drugs are sparse. In a study of needle exchange clients in Stockholm, Sweden,  
155 SARS-CoV-2 prevalence was 5.4% [12], whereas in a survey of people who inject drugs in England,  
156 Wales and Northern Ireland, 11% reported that they had tested positive for COVID-19 [13]. U.S.  
157 estimates among people who are homeless or living in shelters range from 2%-14% [14–16].

158 In our study, SARS-CoV-2 seroprevalence did not differ by country of residence, perhaps reflecting close  
159 social ties between San Diego and Tijuana communities despite the closure of the U.S.-Mexico border. In  
160 a phylogenetic analysis of SARS-CoV-2 sequences from the U.S. and Mexico, those obtained from the  
161 Mexican state of Baja California were more closely related to San Diego than to Mexico City.[17] Although  
162 one half of the San Diego residents in our study had crossed the border and injected drugs in Tijuana in  
163 the last six months, we found no evidence that cross-border mobility was associated with SARS-CoV-2  
164 seropositivity.

165 Consistent with other studies, subjects who were older [6] and who identified as Hispanic, Latinx, or  
166 Mexican [2] were significantly more likely to test SARS-CoV-2 seropositive. This demonstrates that even

167 among the lowest socioeconomic strata in the US and Mexico, ethnic disparities in SARS-CoV-2  
168 seroprevalence persist.

169 We did not observe substance use behaviors, such as smoking, vaping, or use of specific drugs such as  
170 opiates or stimulants to be associated with an elevated risk of SARS-CoV-2 infection, as others have  
171 hypothesized [4,6]. Instead, we observed that circumstances in the risk environment, notably sex work  
172 and incarceration, were associated with significantly higher SARS-CoV-2 seroprevalence.

173 To our knowledge, ours is the first study to show that sex work is independently associated with higher  
174 SARS-CoV-2 prevalence after controlling for potential confounders such as sex, age, and ethnicity. In an  
175 unpublished study in Denmark, SARS-CoV-2 seroprevalence was higher among sex workers (12.2%)  
176 than people experiencing homelessness (6.8%) or the general population (2.9%) [18], but the  
177 independent effects of these and other factors were not assessed.

178 Although the majority of our sample reported that COVID-19 had greatly affected their income and  
179 housing, sex workers may have faced additional hardships following the closure of the U.S.-Mexico  
180 border because of their reliance on sex tourism, and since social distancing is not possible during sexual  
181 transactions. Compared to the rest of the sample, significantly higher proportions of sex workers reported  
182 low or very low food insecurity, and they were more likely to report having been exposed to someone with  
183 COVID-19 than others. This suggests that sex workers may have engaged in higher risk behaviors to  
184 support themselves, placing them at greater risk of SARS-CoV-2 infection. In a study of female sex  
185 workers in Kenya, sexual transactions declined during the pandemic [19] and those most reliant on sex  
186 work reported greater food insecurity, which is consistent with our findings. Among female sex workers in  
187 Nigeria, those with knowledge about COVID-19 were significantly more likely to wear face masks, but less  
188 than half did so [20].

189 Despite concerns about sex workers' vulnerability to COVID-19, few countries provide them aid [19,21]. In  
190 Thailand, the Netherlands and Japan, sex workers were included in COVID-19 government-sponsored  
191 support programs [21], but they are excluded in countries where sex work is criminalized, such as the  
192 U.S. Although sex work is quasi-legal in Tijuana's red light district, those using drugs are less likely to  
193 obtain sex work permits and instead work outside of commercial establishments that could offer

194 protections [22]. In an earlier study, we found that female sex workers in Tijuana who inject drugs were  
195 more vulnerable to offers of unprotected sex in exchange for more money or drugs compared to those  
196 that did not inject [23].

197 Our finding that recent incarceration was independently associated with SARS-CoV-2 seropositivity could  
198 reflect institutional exposures. Over-crowding was implicated in COVID-19 outbreaks in California  
199 correctional institutions [24], including those in the U.S.-Mexico border region. Mitigation included early  
200 release, halting intakes, and eliminating bail, but a recent analysis suggests that considerable potential for  
201 SARS-CoV-2 exposures persist, at least in the California prison system [24]. Similar measures have not  
202 been undertaken in Baja California.

203 Our study also found that over half of those testing SARS-CoV-2 seropositive had not been tested prior to  
204 study enrolment. These findings underscore the need to improve community outreach to provide testing,  
205 vaccines, and treatment, for example using mobile syringe exchange programs.

## 206 **Limitations**

207 Our ability to detect some associations was limited due to statistical power. Ours was a non-random  
208 sample and the cross-sectional study design precludes drawing causal inferences. Participants  
209 experiencing symptoms may have changed behaviors, such as stopped smoking or sought COVID-19  
210 testing.

211 Of note, none of the self-collected swabs tested positive for SARS-CoV-2 RNA. The sensitivity of the  
212 pooling approach could have been impacted by: 1) the viral load of any particular infected individual; 2)  
213 the consistency with which swabs were obtained; 3) storage, shipping, and transport conditions; or 4) of  
214 diluting out (via pooling) any viral SARS-CoV-2 RNA collected below the limit of detection. In this study,  
215 we limited our pools to  $\leq 10$  swabs, and previously validated our approach with up to 30 samples per pool  
216 where the limit of detection was estimated at 2.4 copies/ $\mu\text{L}$  [25]. Therefore, it is unlikely that we  
217 experienced loss of sensitivity due to pooling.

218 Since SARS-CoV-2 antibodies may wane over time especially among patients who are asymptomatic or  
219 mildly symptomatic [26-27], infections that occurred earlier in the epidemic may have gone undetected.

220 However, the majority of participants testing SARS-CoV-2 seropositive had detectable IgM antibody titers,  
221 which is suggestive of recent infection [28]. Some misclassification could have occurred among those  
222 testing indeterminate who were recently infected, but these were few in number and would have tended  
223 to underestimate SARS-CoV-2 prevalence, dampening any observed associations.

224 Since COVID-19 vaccines did not become available to adults 18-65 years of age in San Diego County  
225 until May 15, 2021 and were not available to most adults in Tijuana until after the study period ended, we  
226 were unable to examine the impact of vaccination on SARS-CoV-2 infection. Nevertheless, among the 75  
227 San Diego residents in our sample who were interviewed after May 15, only 9 (9.3%) reported having  
228 received at least one COVID-19 vaccine dose. In comparison, the proportion of adults aged  $\geq 18$  years  
229 who had received at least one COVID-19 vaccine dose in San Diego County through June 24, 2021  
230 exceeded 50% [29].

## 231 **Conclusions**

232 We found that most people who inject drugs in the San Diego-Tijuana border region engaged in  
233 preventive measures to avoid SARS-CoV-2, but since over one-third had evidence of infection, a  
234 binational policy response is warranted beyond the closure of the U.S.-Mexico border. The proportion of  
235 participants who had previously been tested for SARS-CoV-2 or had received COVID-19 vaccine was  
236 very low. Efforts are needed to mitigate risks and provide COVID-19 vaccines to older and Hispanic  
237 people who inject drugs, especially those with less agency to protect themselves, such as those who are  
238 sex workers or incarcerated.

## 239 **Acknowledgements**

240 The authors gratefully acknowledge the La Frontera study team and participants in San Diego and  
241 Tijuana, staff at Genalyte and Fluxergy for assistance interpreting laboratory results, laboratory staff at  
242 the Center for AIDS Research, Dr Pamina Gorbach for assistance with survey measures, Dr. Davey  
243 Smith for helpful suggestions on the study design and Sharon Park for assistance with manuscript  
244 preparation.

## 245 **References**

- 246 1. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. *JAMA* 2020;  
247 323(24): 2466-7.
- 248 2. Macias Gil R, Marcelin JR, Zuniga-Blanco B, Marquez C, Mathew T, Piggott DA. COVID-19 Pandemic:  
249 Disparate Health Impact on the Hispanic/Latinx Population in the United States. *J Infect Dis* 2020;  
250 222(10): 1592-5.
- 251 3. Reitsma MB, Claypool AL, Vargo J, Shete PB, McCorvie R, Wheeler WH, et al. Racial/Ethnic  
252 Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California.  
253 *Health Aff (Millwood)* 2021; 40(6): 870-8.
- 254 4. Volkow ND. Collision of the COVID-19 and Addiction Epidemics. *Ann Intern Med* 2020; 173(1): 61-2.
- 255 5. Genberg BL, Astemborski J, Piggott DA, Woodson-Adu T, Kirk GD, Mehta SH. The health and social  
256 consequences during the initial period of the COVID-19 pandemic among current and former people  
257 who inject drugs: A rapid phone survey in Baltimore, Maryland. *Drug Alcohol Depend* 2021; 221:  
258 108584.
- 259 6. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use  
260 disorders: analyses from electronic health records in the United States. *Mol Psychiatry* 2021; 26(1):  
261 30-9.
- 262 7. Zolopa C, Hoj S, Bruneau J, Meeson JS, Minoyan N, Raynault MF, et al. A rapid review of the impacts  
263 of "Big Events " on risks, harms, and service delivery among people who use drugs: Implications for  
264 responding to COVID-19. *Int J Drug Policy* 2021; 92: 103127.
- 265 8. U.S. Department of Agriculture (USDA) - Economic Research Service. Food Security in the U.S. -  
266 Measurement. 2020. [https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in-](https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in-the-us/measurement/#measurement)  
267 [the-us/measurement/#measurement](https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in-the-us/measurement/#measurement) (accessed June 29 2021).
- 268 9. Food and Drug Administration (FDA). Maverick™ SARS-CoV-2 Multi-Antigen Serology Panel v2  
269 01030ART-01. <https://www.fda.gov/media/142915/download> (accessed June 16 2021).
- 270 10. Ikegami S, Benirschke RC, Fakhrai-Rad H, Motamedi MH, Hockett R, David S, et al. Target specific  
271 serologic analysis of COVID-19 convalescent plasma. *PLoS One* 2021; 16(4): e0249938.
- 272 11. Consulado General de México en San Diego. Presentation of the results of the "Survey on Prevalence  
273 of Covid-19 in Baja California". 2021.  
274 [https://consulmex.sre.gob.mx/sandiego/index.php/comunicados-2020/782-survey-on-prevalence-](https://consulmex.sre.gob.mx/sandiego/index.php/comunicados-2020/782-survey-on-prevalence-of-covid-19-in-baja-california)  
275 [of-covid-19-in-baja-california](https://consulmex.sre.gob.mx/sandiego/index.php/comunicados-2020/782-survey-on-prevalence-of-covid-19-in-baja-california) (accessed July 15 2021).
- 276 12. Lindqvist K, Wallmofeldt C, Holmen E, Hammarberg A, Kaberg M. Health literacy and changes in  
277 pattern of drug use among participants at the Stockholm Needle Exchange Program during the  
278 COVID-19 pandemic. *Harm Reduct J* 2021; 18(1): 52.
- 279 13. Croxford S, Emanuel E, Ibitoye A, Njoroge J, Edmundson C, Bardsley M, et al. Preliminary indications  
280 of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the  
281 impact on access to health and harm reduction services. *Public Health* 2021; 192: 8-11.
- 282 14. Rogers JH, Link AC, McCulloch D, Brandstetter E, Newman KL, Jackson ML, et al. Characteristics of  
283 COVID-19 in Homeless Shelters : A Community-Based Surveillance Study. *Ann Intern Med* 2021;  
284 174(1): 42-9.
- 285 15. Yoon JC, Montgomery MP, Buff AM, Boyd AT, Jamison C, Hernandez A, et al. COVID-19 Prevalence  
286 among People Experiencing Homelessness and Homelessness Service Staff during Early Community  
287 Transmission in Atlanta, Georgia, April-May 2020. *Clin Infect Dis*, 2020.  
288 <https://www.ncbi.nlm.nih.gov/pubmed/32898272> (accessed Sep 8).
- 289 16. Mosites E, Parker EM, Clarke KEN, Gaeta JM, Baggett TP, Imbert E, et al. Assessment of SARS-CoV-2  
290 Infection Prevalence in Homeless Shelters - Four U.S. Cities, March 27-April 15, 2020. *MMWR Morb*  
291 *Mortal Wkly Rep* 2020; 69(17): 521-2.

- 292 17. San Diego Epidemiology and Research for COVID Health (SEARCH). SARS-CoV-2 Genomics. 2021.  
293 <https://searchcovid.info/genomics/> (accessed June 29 2021).
- 294 18. Røthlin Eriksen AR, Fogh K, Hasselbalch RB, Bundgaard H, Nielsen S, Jørgensen C, et al. SARS-CoV-2  
295 antibody prevalence among homeless people, sex workers and shelter workers in Denmark: a  
296 nationwide cross-sectional study. medRxiv 2021: 2021.05.07.21256388.
- 297 19. Kavanagh NM, Marcus N, Bosire R, Otieno B, Bair EF, Agot K et al. Health and Economic Outcomes  
298 Associated With COVID-19 in Women at High Risk of HIV Infection in Rural Kenya. JAMA Network  
299 Open 2021; 4(6): e2113787-e.
- 300 20. Avwioro G, Egwunyenga A, Adjekuko C, Mgbere O, Odibo E, Iyiola S, et al. Commercial Sex Work  
301 During Novel Coronavirus (SARS-CoV-2) Era in the Niger Delta Region: Relationships Between  
302 Knowledge, Preventive Practice, and Transmission Potential. Int J Womens Health 2021; 13: 509-23.
- 303 21. Platt L, Elmes J, Stevenson L, Holt V, Rolles S, Stuart R. Sex workers must not be forgotten in the  
304 COVID-19 response. Lancet 2020; 396(10243): 9-11.
- 305 22. Sirotin N, Strathdee SA, Lozada R, Nguyen L, Gallardo M, Vera A, et al. A comparison of registered  
306 and unregistered female sex workers in Tijuana, Mexico. Public Health Rep 2010; 125 Suppl 4: 101-9.
- 307 23. Strathdee SA, Lozada R, Martinez G, Vera A, Rusch M, Nguyen L, et al. Social and structural factors  
308 associated with HIV infection among female sex workers who inject drugs in the Mexico-US border  
309 region. PLoS One 2011; 6(4): e19048.
- 310 24. Chin ET, Ryckman T, Prince L, Leidner D, Alarid-Escudero F, Andrews JR et al. Covid-19 in the  
311 California State Prison System: An Observational Study of Decarceration, Ongoing Risks, and Risk  
312 Factors. medRxiv, 2021. <https://www.ncbi.nlm.nih.gov/pubmed/33758868> (accessed Mar 8).
- 313 25. Rawlings SA, Ignacio C, Porrachia M, Du P, Smith DM, Chaillon A. No Evidence of SARS-CoV-2 Seminal  
314 Shedding Despite SARS-CoV-2 Persistence in the Upper Respiratory Tract. Open Forum Infect Dis  
315 2020; 7(8): ofaa325.
- 316 26. Ibarrodo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of  
317 Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 2020; 383(11): 1085-7.
- 318 27. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of  
319 asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26(8): 1200-4.
- 320 28. Chen Y, Li P, Ding Y, Liu M, Liu L, Yi B, et al. Epidemiological feature, viral shedding, and antibody  
321 seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic  
322 COVID-19 patients. J Infect Public Health 2021; 14(7): 845-51.
- 323 29. County of San Diego. COVID-19 Vaccinations Report - San Diego County Residents with COVID19  
324 Vaccinations by Age Group. 2021.  
325 [https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/Epidemiology/COVID-](https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/Epidemiology/COVID-19%20Vaccinations%20by%20Age%20Group.pdf)  
326 [19%20Vaccinations%20by%20Age%20Group.pdf](https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/Epidemiology/COVID-19%20Vaccinations%20by%20Age%20Group.pdf) (accessed June 29 2021).

327